CA-KONG-INC.
11.5.2021 15:02:10 CEST | Business Wire | Press release
Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect , a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta , Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/
The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building applications instead of wasting time building pipes; developers gain architectural freedom to choose the best language, protocol and cloud services for building their microservices; and operators deploy APIs consistently across any infrastructure to support the hybrid or multi-cloud deployment patterns that the business requires for performance, cost, privacy or regulatory compliance reasons.
With the GA release, Kong is introducing a flexible consumption-based pricing model that brings enterprise-class tech within reach of individual developers as well as large teams. Usage of Kong Konnect is metered, enabling users to pay solely for the number of services used.
Kong Konnect is available in three plan tiers:
- Kong Konnect Free allows developers to instantly try out the product without having to go through an enterprise sales representative.
- Kong Konnect Plus offers a freemium model with a pay-as-you-go, credit card-based option that provides a simple way for developers or operators on small teams to quickly start using the services they need right now.
- Kong Konnect Enterprise is for organizations that want to use the platform as a whole; it provides connectivity with enterprise-grade security, scalability and observability across any cloud, platform and protocol to help teams build powerful digital services and experiences.
“Kong Konnect addresses a massive challenge companies face as they enter digital transformation 2.0, which is characterized by an exponential increase in the volume and variety of connections that need to be activated and secured with lightning-fast speed,” said Marco Palladino, CTO and co-founder of Kong Inc. “One day, we will look back in amazement to realize that developers were spending a lot of time building the plumbing, and writing the networking and security code for each service on each platform. Automated cloud connectivity is inevitable – from gateway to service mesh across every cloud, Kubernetes and VMs – and market-leading companies already know this and are offloading this function so that their top talent can focus on application design and feature development so they can continue to outpace the competition.”
A Service Connectivity Platform That Offers Connections for Everyone
With a modular approach, end users can access capabilities delivered as functional modules and provision different types of runtimes on-demand without requiring purchase of the entire platform. Users are able to select and consume only the features they need directly through the Kong Konnect interface, removing barriers to building next-generation applications and services.
Kong Konnect provides reliable, secure and observable connectivity for services across any infrastructure. The SaaS-based management plane accelerates deployments and provides access to functionality modules, including the Kong ServiceHub , Kong Vitals , Kong Runtime Manager and the Kong Developer Portal . Kong Immunity and Insomnia continue to be available for self-management to customers. The runtimes – Kong Gateway and Kong Mesh – are self-managed and provide the flexibility to support any hybrid or multi-cloud deployment pattern.
To get started with Kong Konnect, please visit https://konghq.com/kong-konnect/ .
About Kong Inc.
Kong creates software and managed services that connect APIs and microservices natively across and within clouds, Kubernetes, data centers and more using intelligent automation. Built on an open source core, Kong’s service connectivity platform enables digital innovation by allowing organizations to reliably and securely manage the full lifecycle of APIs and services for modern architectures, including microservices, serverless and service mesh. By providing developer teams with unprecedented architectural freedom, Kong accelerates innovation cycles, increases productivity, and seamlessly bridges legacy and modern systems and applications. For more information about Kong, please visit konghq.com or follow @thekonginc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005311/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom